Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Organogenesis Holdings ( (ORGO) ).
On June 23, 2025, Organogenesis Holdings held its Annual Meeting of Stockholders where several key proposals were voted on and approved. The meeting included the re-election of Garrett Lustig to the board of directors and the election of other directors to serve until the next annual meeting. Additionally, stockholders approved the compensation for named executive officers and the issuance of over 20% of Class A common stock upon conversion of Series A Convertible Preferred Stock, which may be deemed a change of control under Nasdaq rules. The appointment of RSM US LLP as the independent registered public accounting firm for 2025 was also ratified.
The most recent analyst rating on (ORGO) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Organogenesis Holdings stock, see the ORGO Stock Forecast page.
Spark’s Take on ORGO Stock
According to Spark, TipRanks’ AI Analyst, ORGO is a Neutral.
Organogenesis Holdings’ stock score is primarily affected by its financial performance challenges, including declining revenue and profitability, negative cash flow, and valuation concerns with a negative P/E ratio. Technical analysis suggests bearish momentum, further weighing on the stock. Despite these challenges, reaffirmed guidance and strategic initiatives discussed in the earnings call provide some optimism for potential recovery.
To see Spark’s full report on ORGO stock, click here.
More about Organogenesis Holdings
Average Trading Volume: 1,429,894
Technical Sentiment Signal: Sell
Current Market Cap: $409.7M
See more insights into ORGO stock on TipRanks’ Stock Analysis page.